#JPM21: Reshma Kewalramani is on the hunt for 'mid-to late-stage assets,' new tools to replenish Vertex pipeline
It’s her first JP Morgan as CEO of Vertex, and Reshma Kewalramani is hitting the ground running.
The partnerships she inherited from predecessor Jeff Leiden have produced a slate of programs that, while promising, are either preclinical or just wrapping up human proof-of-concept. But for 2021, Kewalramani has outlined a plan to bring in more mid-to late-stage assets — alongside and tools to expand our toolkit.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,500+ biopharma pros reading Endpoints daily — and it's free.